Flow Cytometry Congress

When

2019年10月10-11日
Registration from 8am

Where

英國,倫敦
London Heathrow Marriott Hotel

Flow Cytometry Congress
-流式細胞技術學會-
日期:2019年10月10-11日
地點:英國,倫敦,London Heathrow Marriott Hotel
Choose your language
Chinese
Japanese
Korean
English

Flow Cytometry Congress

這個活動可以讓您了解流式細胞儀在細胞分析和癌症診斷及治療方面的最新技術發展和應用。重點關注流式細胞和鞘液設計的進步,新熒光團的開發以及下一代檢測系統。在應用相關單元則涵括了細胞表面抗原的分析,細胞健康和死亡狀態評估,細胞分選技術和腫瘤學中的藥物開發。

這個學會是以癌症免疫療法相關研究及技術為主題的一系列活動之一。報名參加這個學會,您除了可以聽取這五個學會中將進行的100多場演講之外,更可拓展您橫跨各專門領域的人脈,吸收到嶄新的知識。

2019年10月10日(四) – 策略及技術


主題演講: 白血病診斷所需的半監督資料叢集和機器學習
RICHARD SCHEUERMANN, Director, Adjunct Professor, J. Craig Venter Institute
The current approach for identifying diagnostic cell populations from cytometry data in clinical labs is based on manual gating analysis, which is subjective and labor-intensive, especially with higher-dimensional complex datasets. Over the last several years, our group and others have developed a suite of computational tools and machine learning for the processing and analysis of cytometry data. To illustrate the potential use of these methods in a clinical diagnostic setting, we will present the results of a pilot project to optimize and apply a selected set of computational and machine learning methods for the automated identification of chronic lymphocytic leukemia (CLL) cells in patient samples

主題演講: 成像流式細胞儀 - 結合強力統計分析工具的流式細胞技術和信息豐富的顯微鏡
ANNE WILSON, Director of the Flow Cytometry Facility, University of Lausanne (UNIL) Switzerland)
Conventional flow cytometry is a statistically powerful technology used to analyze antigen expression in populations of cells at the single cell level. It however provides little information about cell morphology, interactions between cells and localization of antigens or molecules on or within the cells, or, co-localization of molecules to cytoplasmic or nuclear structures. Imaging Flow cytometry provides all this detailed information and more at the single cell level on large numbers of cells, combining the best features of both conventional flow cytometry and microscopy. This presentation provides examples of the power and diversity of this technology.

Presentation


Morning Refreshments / Poster Presentations


Seeing more by targeting less – development of probes, prodrugs and provenance
RACHEL ERRINGTON, Chair and Principle Investigator of the Tissue MicroEnvironment Group Division of Cancer and Genetics, School of Medicine, Cardiff University
The development of both fluorescent probes is an important endeavour in cancer research useful for the drug discovery pipeline. Our simple working hypothesis is that the cellular uptake and subcellular localisation of molecules can provide important information on the status of a cell. Core to the Deep-RedAnthraQuinone (DRAQ) probe family is that the spectral-window for both excitation and emission sits in the red (>600nm) thereby making the probe suitable for studies on single cells (2D) through to thick tissue models (3D ie spheroids and organoids). Our key undertaking has been to design molecules that allow us to tune their capacity to label the nucleus versus other cellular compartments providing a greater range of signal readouts, for tracking behaviour and the emergent properties of populations

The Development of a Multicolour Antibody Panel for Mouse Bone Marrow Stromal Cells - Challenges and Breakthroughs
JANE SRIVASTAVA, Flow Cytometry Facility Manager, South Kensington Campus, Imperial College London
Why is this panel important?
• Why we chose these specific markers and fluorophores
• Some tips for the challenges of working with a large multicolour antibody panel with rare cells
• Final panel considerations and preliminary data
• Future work


Lunch


Implementation of Multi-Parameter Flow Cytometry Assays in Clinical Trials
VILMA DECMAN, Associate Director Flow Cytometry, Bristol-Myers Squibb
Flow cytometry is a powerful technique in the research, drug development and clinic as it allows for the examination of multiple targets on various cell subsets from a limited sample size. Its ability to identify and enumerate different cellular markers and track them across time and treatment aids in understanding of disease pathology, toxicological assessment of new drugs and their efficacy. This talk will concentrate on implementation of multi-parameter flow cytometry in clinical trials including:
• Understanding of biomarker needs in development of high-dimensional flow cytometry assays
• Design and optimization of panels; potential pitfalls
• Validation of assay/standardization
• Sample logistics
• New technology platforms

An in vivo approach to the early photoacoustic detection of infectious diseases and blood conditions
VLADIMIR ZHAROV, Professor, Director, University of Arkansas for Medical Sciences, Arkansas Nanomedicine Center

60 MINUTE INTERACTIVE WORKSHOP


Afternoon Refreshments / Poster Presentations


Standardizing technical practise across labs - developing an automated shared resource library
CHRIS GROVES, Senior Manager, MedImmune

Data-driven cytometry
RYAN BRINKMAN, Professor, Medical Genetics, University of British Columbia Distinguished Scientist, BC Cancer CEO, Cytapex Bioinformatics Inc.
Manual analysis of flow cytometry data is subjective and time consuming. Automated algorithms have reached a level of maturity that enables them to match and, in many cases, exceed the results produced by human experts. The current state-of-the-art will be reviewed though example applications of these algorithms in automating the entire data analysis pipeline. Examples will include automated quality checking at the event and sample level, rapid, robust and reproducible automated gating and biomarker discovery algorithms. The utility of these algorithms will be shown through their application on patient data for basic research, clinical trials and drug discovery.


Networking Drinks Reception


2019年10月11日(五) - 細胞級分析及其在腫瘤治療的應用

主題演講: 從幹細胞到血液細胞:分化途徑的流式細胞技術
FRANK PREIJERS, Radboud University Medical Center, Nijmegen, The Netherlands
Flow cytometry (FCM) is increasingly used in clinical laboratories for diagnosis of various hematological disease. The rapid and sensitive multi-parameter detection renders FCM to a powerful tool to distinguish malignant cells from normal. Pattern recognition of fluorescence expression levels of conjugates and combinations in the various cells activation stages is hereby essential. However, before aberrancies can be established, the normal hematopoiesis must be studied. Bone marrow contains all differentiation stages of hematopoiesis. The maturation can be monitored by changes in immunophenotype, identified by a unique combination of MoAbs.
Each antigen is expressed by an appropriate expression pattern during the maturation. Frequently, neoplastic cells possess aberrant immunophenotypes. More or less antigens and antigen expression on different levels can be found in these leukemic cells. This implies that knowledge of the normal cell maturation patterns facilitates recognition of malignant cells. We studied the maturation pathways from stem cells to myeloid, monocytic and erytroid lineage cells using a 10-color NaviosTM (Beckman Coulter) and KaluzaTM analysis software.

Identifying new forms of cell death - using flow cytometry to explore cell fate
GARY WARNES Flow Cytometry Core Facility Manager, Blizard Institute, Barts and London School of Medicine & Dentistry, Queen Mary London University
• RIP3 and Caspase-3 intracellular labelling with a fixable live/dead probe allows the flow cytometric detection of necroptosis (RIP3high+ve/Caspase-3-ve) , apoptosis (RIP3-ve/Caspase-3+ve) and RIP1-dependent apoptosis (RIP3+ve/Caspase-3+ve)
• Further labelling with LC3B allows the detection of autophagic cells
• Additional labelling with H2AX and PARP allows further identification of DNA damage, hyper-action of PARP and parthanatos
• Incidences of RCD were modulated by the use of zVAD and Necrostain-1
• Autophagy was shown to protect cells by reducing DNA damage
• Use of MitoTracker and violet live cell caspase probe allows the identification of necroptosis and apoptosis in unfixed cells
• Additional use of fixable probes for mitochondrial function and Reactive Oxygen Species (ROS) extends the number of identifiable cell death populations to 500


Morning Refreshments / Poster Presentations


Starting up clinical trials with TCR-modified T cells in solid cancers
DAVID BAKER Senior Research Scientist, AstraZeneca
• The high-throughput flow cytometry capability at AZ and examples of how this has been used.
• Applications of high-throughput flow cytometry in immuno-oncology projects (assays such as T-cell proliferation, activation, tumour killing assays).

Applications of flow cytometry in early phase oncology trials
STEPHANIE TRAUB,Cancer Research UK
The presentation will outline the use of flow cytometry in early phase clinical development with relevant examples of commonly encountered challenges and suggested solutions.


Lunch


Developing a GUCY2C-Targeted Adoptive T Cell Therapy
FRIDTJOF LUND-JOHANSEN, Head of flow cytometry core facility, Oslo University Hospital, Norway
Proteomics is still a small discipline where the research front is driven by a few laboratories with unrestricted access to mass spectrometry (MS). With MAP, we put the power of proteomics into the hands of flow cytometry (FCM) users. Bead-based arrays with a multiplexing capacity up to 5000 provide the convenience and throughput needed to take proteomics to the next level. The challenge lies in changing the mindset that keeps the western blot on top of the list of the most popular antibody applications. The FCM version is called Western-MAP and yields results for thousands of antibodies in parallel. In Native-MAP, proteins are separated by size exclusion chromatography for large-scale analysis of protein complexes. Thus, MAP turns the flow cytometer into a high throughput proteomics machine.

Analysing t cells for neo-antigen specificity
PIA KVISTBORG (Reserved), Junior Group Leader, NKI Amsterdam


Chair’s Closing Remarks / Conference Close


 

* 活動內容有可能不事先告知作更動及調整。

議程

由於這個學會針對的是參與研究流式細胞技術 - 這個提供了細胞特性之可定量化數據所需的重要方法之技術領域人士,所以將吸引350以上該領域的專家。

Download the Agenda (PDF)

演講者

贊助商

所有贊助商名單

地點

London Heathrow Marriott Hotel

London Heathrow Marriott900

Bath Road, Harlington, Hayes, Middlesex, UB3 5AN

海報發表

海報發表除了在休息時間之外,更與分組會議單元同時進行。製藥公司和研究機關的研究人員製所作的海報,會在通過學會審核之後,於會場內指定區域展示。

我們還會向所有與會者發放海報電子書,如果您願意,可以在會議結束後以PDF格式分享您的海報(可自由選擇)。

無論是尋找資金,就業機會還是只是想與志同道合,專心致力的研究團隊分享您的工作成果,會場內的海報都是讓您吸引眾人注目的寶貴機會。

為了在論壇上展示海報,您需要報名登記參加學會。海報展示空間有限,將依報名順序加以審核,懇請提早報名以免向隅。

我們向行業代表收取100英鎊的管理費,用於提供海報展示區和展板,指南等共同費用。代表學術機構而非營利組織的人則免收這筆費用。

海報發表的申請方法

請填寫專用表格 (下列鏈接可下載) ,在2019年9月20日前提交。但因空間有限,敬請早日申請以免向隅,如有任何問題請洽詢聯絡處。

學會的贊助商

募集贊助商

成為這個學會的贊助商或參展商,您可在融洽的氣氛中,一面和專家們交流彼此的意見,同時也有機會和各種組織代表進行官方或非官方會談,以建立彼此的合作關係。

此外我們更準備了各種贊助商配套方案,您可考量自身的預算及業務需求,選擇能讓您獲得最大投資收益的方案。

如果您有除此之外,成為贊助商來開展您宣傳活動的其他建議,也歡迎您隨時與我們連絡,我們將配合您的需求提供各種提案。

可事前預約的二十分鐘一對一個別會談

在主要會議議程的分組會議期間將舉行一系列事先預約的二十分鐘個別會談,選擇您想要會見的代表。在會議期間Global Engage的團隊將隨時待命,確保您的所有會議按時舉行。

主要會議前後的研討會

在主要會議前後,將舉辦為了對特定主題有興趣的與會者所辦的全天或半天研討會。Global Engage將協助您在研討會上進行宣傳活動,並確保夠多人出席。

學會開幕前的行銷和品牌宣傳

您也可利用Global Engage的資料庫來進行行銷,更可揭示海報,成為休息和午餐會、招待會、海報單元的贊助商來提升您的品牌知名度。此外我們也另外提供可在發給與會者的掛繩,和學會資料袋上印刷標誌以提升品牌知名度的選項。

參展

會期中,您可在會場內所設的專用區向所有的與會者發表您的技術及產品。展會區同時也是休息及午餐會,第一天傍晚舉行的招待會的會場。

演講

演講的形態

  • 30分鐘的演講
  • 以主持人或小組成員身分參加30分鐘專題研討會
  • 在學會的議程中召開1小時的研討會
募集贊助商

詳細內容請洽詢GII聯絡處。

包括簽證等各種海關所需文件,以及展示用品的通關手續皆由展商企業各自負責。

展示相關的安排(企業介紹、公司商標、提供與會者目錄中的展商資訊登錄、展示空間的裝潢、用品訂購、展示用品的擺設搬運、展示空間的文件申請、保險等)請直接與主辦方連繫。

旅遊相關疑問(住宿、機票)、當地翻譯人員、飛行與意外保險等問題,將有另外的專門業者分別提供服務。

Flow Cytometry Congress的贊助商相關詳情請洽詢聯絡處。

關於與會者、配套方案、新募集情報等詳細資訊,請洽詢聯絡處。我們將竭誠為您提供關於您評估這場活動所需的所有資訊。

媒體合作夥伴

  • 247 Updates
  • Bentham Science
  • Biocompare
  • Biotechgate
  • EIN Presswire
  • Global Information
  • Pharma Journalist
  • PharmaVOICE
  • SciDoc Publishers
  • Pharmaceutical Tech
 
免費電子郵件通知服務